TCG Crossover Management’s Viridian Therapeutics VRDN Stock Holding History

TCG Crossover Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-663,610	Closed	-$16.9M	–	23
2023 Q1	$16.9M	Sell	663,610 -320,000	-33%	-$10.3M	3.29%	13
2022 Q4	$28.7M	Sell	983,610 -180,390	-15%	-$4.16M	5.07%	8
2022 Q3	$23.9M	Sell	1,164,000 -150,000	-11%	-$2.7M	7.16%	4
2022 Q2	$15.2M	Hold	1,314,000	–	–	6.46%	7
2022 Q1	$24.3M	Hold	1,314,000	–	–	9.75%	2
2021 Q4	$26M	Buy	+1,314,000	New	+$24.5M	12.16%	2

Other funds holding VRDN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return